Fig. 2

TRAF3IP2-AS1 deficiency induces development of NONO-TFE3 tRCC. a Schematic illustration of CRISPR/Cas9-based Synergistic Activation Mediator (SAM) system. b The RNA level of TRAF3IP2-AS1 was analyzed by qRT-PCR assay in UOK109 transfected with dCas9 and guide RNA targeting TRAF3IP2-AS1 promoter (gTRAF3IP2-AS1). c The RNA level of TRAF3IP2-AS1 was analyzed by qRT-PCR assay in 786-O transfected with siRNA and antisense oligonucleotides (ASOs). d–f The effects of TRAF3IP2-AS1 overexpression or knockdown on the proliferation of UOK109 and 786-O cells, respectively, were examined by CCK-8 assay (d), colony formation assays (e) and tumor sphere formation (f). g EdU assays were used to detect the proliferation rate of UOK109 and 786-O cells after transfection for 48 h. h Cell cycle was analyzed using flow cytometry after transfection for 48 h. i Cell apoptosis was analyzed via flow cytometry using an Annexin V/PI Kit after transfection for 48 h. j Migration and invasion assays were performed with transfected cells using Transwell inserts. The data are presented as the mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001